Diabetes: Insulet and Dexcom call it quits on development agreement

February 7, 2013 by Arezu Sarvestani

Insulet and Dexcom decide not to pursue a joint development agreement to integrate Dexcom's continuous glucose monitoring technology with Insulet's insulin-infusing OmniPod.

Broken handshake illustration

Diabetes technology makers Insulet (NSDQ:PODD) and  (NSDQ:DXCM) abandoned a 5-year-old joint development deal that would have merged Dexcom's continuous glucose monitoring technology with Insulet's OmniPod insulin delivery system, officials confirmed with MassDevice.com today.

The pair parted ways over differences in their vision for the future of diabetes management technology. Each wants to lower the quantity of devices a diabetic patient must carry in order to manage the disease, but are pursuing diverging avenues for integrating existing monitoring and treatment technologies.

Insulet aims to reduce the number of skin-worn devices while Dexcom is looking to shift its monitoring systems onto the smartphones that patients already have in their pockets.

Sign up to get our free newsletters delivered right to your inbox.

Insulet's already moved on to the next potential partner, an unnamed private company with technology that aims to allow OmniPod technology to deliver insulin and gather continuous blood glucose data through a single site rather than through 2 devices attached to the skin.

Insulet had hinted at the change in direction earlier this year when presenting at the J.P. Morgan conference in San Francisco.